Claims for Patent: 8,003,792

Summary for Patent: 8,003,792

Title:	Bicyclic anilide spirolactam CGRP receptor antagonists
Abstract:	The present invention is directed to compounds of Formula I: ##STR00001## (where variables A.sup.1, A.sup.2, B, J, K, m, n, R.sup.4, R.sup.5a, R.sup.5b and R.sup.5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Inventor(s):	Bell; Ian M. (Harleysville, PA), Theberge; Cory R. (King of Prussia, PA), Stump; Craig A. (Pottstown, PA), Zhang; Xufang (Dresher, PA), Gallicchio; Steven N. (Wyndmoor, PA), Zartman; C. Blair (Hatfield, PA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	11/662,703
Patent Claims:	1. A compound of formula I: ##STR00119## wherein: B is a bicycloheterocycle selected from the group consisting of: ##STR00120## where T, U, V, W, X and Y are each independently a carbon atom or a nitrogen atom, wherein no more than two of T, U, V and W, and no more than three of T, U, V, W, X and Y, are a nitrogen atoms, B is unsubstituted or substituted with 1-5 substituents each independently selected from R.sup.1, R.sup.2, R.sup.3a and R.sup.3b, wherein R.sup.1, R.sup.2, R.sup.3a and R.sup.3b are independently selected from: (1) --C.sub.1-6alkyl, which is unsubstituted or substituted with 1-5 substituents each independently selected from: (a) fluoro, (b) --CO.sub.2R.sup.9, wherein R.sup.9 is independently selected from: --C.sub.1-4alkyl and --C.sub.3-6cycloalkyl, and (c) --CONR.sup.10aR.sup.11a, wherein R.sup.10a and R.sup.11 are each independently selected from: hydrogen and --C.sub.1-6alkyl, (2) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolidinyl, thiazolyl, tetrahydrofuryl, and tetrahydrothiopyranyl, which phenyl or heterocycle is unsubstituted or substituted with 1-5 substituents each independently selected from: (a) --C.sub.1-6alkyl, which is unsubstituted or substituted with 1-3 fluoro, (b) halo, (c) --CO.sub.2R.sup.9, (d) --(CO)R.sup.9, (e) oxo, (f) --S--C.sub.1-4alkyl, (g) --S(O)--C.sub.1-4alkyl, and (h) --SO.sub.2--C.sub.1-4alkyl, (3) halo, (4) --NR.sup.10R.sup.11, wherein R.sup.10 and R.sup.11 are each independently selected from: hydrogen, and --COR.sup.9; or R.sup.3a and R.sup.3b and the carbon atom to which they are attached are joined to form a ring selected from cyclohexyl, piperidinyl, tetrahydropyranyl, and tetrahydrothiopyranyl, which ring is unsubstituted or substituted with 1-5 substituents each independently selected from: (a) --C.sub.1-6alkyl, which is unsubstituted or substituted with 1-3 substituents each independently selected from: halo, (b) hydroxy, (c) --CO.sub.2R.sup.9, and (d) oxo; A.sup.1 and A.sup.2 are each independently selected from: a bond and --CR.sup.13R.sup.14--, wherein R.sup.13 and R.sup.14 are hydrogen, wherein one of A.sup.1 and A.sup.2 is optionally absent; J is independently selected from: .dbd.C(R.sup.6a)--, --CR.sup.13R.sup.14-- and --C(.dbd.O)--; K is independently selected from: .dbd.C(R.sup.6b)--, --CR.sup.13R.sup.14--, --C(.dbd.O)--; R.sup.4 is independently selected from: hydrogen, C.sub.1-6 alkyl which is unsubstituted or substituted with 1-6 fluoro, C.sub.5-6 cycloalkyl, benzyl and phenyl; R.sup.5a, R.sup.5b and R.sup.5c are hydrogen; R.sup.6a and R.sup.6b are hydrogen; or R.sup.6a and R.sup.6b and the atom(s) to which they are attached are joined to form a ring selected from phenyl, pyridyl and pyrimidinyl, which ring is unsubstituted or substituted with 1-5 substituents independently selected from halo; m is 1; n is 1; and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof. 2. The compound of claim 1, of the formula Ic: ##STR00121## and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof. 3. The compound of claim 1, of the formula Ie: ##STR00122## and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof. 4. The compound of claim 1, of the formula If: ##STR00123## and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof. 5. The compound of claim 1, of the formula Ig: ##STR00124## and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof. 6. The compound of claim 1, wherein B is selected from: ##STR00125## ##STR00126## where B is unsubstituted or substituted with 1-5 substituents selected from R.sup.1, R.sup.2, R.sup.3a. 7. The compound of claim 1, wherein B is selected from: 2-oxobenzimidazolinyl, indolyl, indolinyl, 2-oxoindolinyl, 2-oxoazabenzimidazolinyl and azaindolyl. 8. The compound of claim 1, wherein J is selected from: .dbd.C(R.sup.6a)-- and --CH.sub.2--. 9. The compound of claim 1, wherein K is selected from: .dbd.C(R.sup.6b)--, --CH.sub.2--, and --C(.dbd.O)--. 10. The compound of claim 1, wherein R.sup.4 is selected from: hydrogen and --C.sub.1-6alkyl which is unsubstituted or substituted with fluoro. 11. A compound selected from: ##STR00127## ##STR00128## ##STR00129## ##STR00130## ##STR00131## ##STR00132## ##STR00133## ##STR00134## and pharmaceutically acceptable salts and individual diastereomers thereof. 12. A pharmaceutical composition which comprises an inert carrier and the compound of claim 1. 13. A pharmaceutical composition comprising: a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a second agent selected from serotonin agonists, analgesics, anti-inflammatory agents, and anticonvulsants. 14. The composition of claim 13, wherein said second agent is selected from a 5HT.sub.1B/1D agonist, a 5HT.sub.1D agonist, and a 5HT.sub.1F agonist. 15. The composition of claim 14, wherein said second agent is selected from rizatriptan, sumatriptan, naratriptan, zolmitriptan, almotriptan, eletriptan, avitriptan, frovatriptan, LY334370 and PNU-142633. 16. The composition of claim 13, wherein said second agent is selected from ergotamine and dihydroergotamine. 17. The composition of claim 13, wherein said second agent is aspirin or acetaminophen. 18. The composition of claim 13, wherein said second agent is a glucocorticoid. 19. The composition of claim 13, wherein said second agent is a non-steroidal anti-inflammatory agent. 20. The composition of claim 19, wherein said second agent is selected from ibuprofen, ketoprofen, fenoprofen, naproxen, indomethacin, sulindac, meloxicam, piroxicam, tenoxicam, lornoxicam, ketorolac, etodolac, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, diclofenac, oxaprozin, apazone, nimesulide, nabumetone, tenidap, etanercept, tolmetin, phenylbutazone, oxyphenbutazone, diflunisal, salsalate, olsalazine and sulfasalazine. 21. The composition of claim 13, wherein said second agent is an anticonvulsant selected from topiramate, zonisamide, divalproex sodium, pregabalin, gabapentin, levetiracetam, lamotrigine and tiagabine. 22. A pharmaceutical composition comprising: a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a second agent selected from angiotensin II antagonists, angiotensin I antagonists, angiotensin converting enzyme inhibitors, and renin inhibitors. 23. The composition of claim 22, wherein said second agent is selected from losartan, candesartan, candesartan cilexetil, irbesartan, valsartan, eprosartan, telmisartan, olmesartan, medoxomil, captopril, benazepril, quinapril, perindopril, ramipril, trandolapril, lisinopril, and enalapril. 24. A pharmaceutical composition comprising: a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a second agent selected from anti-anxiety agents and neuroleptics. 25. The composition of claim 24, wherein said second agent is selected from, diazepam, alprazolam, chlordiazepoxide, olanzapine, droperidol, prochlorperazine, chlorpromazine and quetiapine. 26. A pharmaceutical composition comprising: a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a second agent selected from beta-blockers and calcium channel blockers. 27. The composition of claim 26, wherein said second agent is selected from timolol, propanolol, atenolol, metoprolol, nadolol, flunarizine, diltiazem, amlodipine, felodipine, nisolipine, isradipine, nimodipine, lomerizine, verapamil, nifedipine, prochlorperazine and civamide. 28. A pharmaceutical composition comprising: a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a second agent selected from anti-depressants, selective serotonin reuptake inhibitors, and NE reuptake inhibitors. 29. The composition of claim 28, wherein said second agent is selected from amitriptyline, nortriptyline, clomipramine, imipramine, venlafaxine, doxepin, protriptyline, desipramine, trimipramine, fluoxetine, paroxetine, sertraline, duloxetine, escitalopram, and citalopram. 30. A pharmaceutical composition comprising: a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a second agent selected from botulinum toxins A or B. 31. A pharmaceutical composition comprising: a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a second agent selected from vanilloid receptor antagonists, adenosine 1 antagonists, NR2B antagonists, substance P antagonists, granzyme B inhibitors, endothelin antagonists, norepinephrin precursors, nitric oxide synthase inhibitors, neuroleptics, bradykinin antagonists, gap junction inhibitors, AMPA/KA antagonists, sigma receptor agonists, chloride channel enhancers, monoamine oxidase inhibitors, opioid agonists, and leukotriene receptor antagonists. 32. The composition of claim 31, wherein said second agent is selected from montelukast and zafirlukast. 33. The composition of claim 31, wherein said second agent is aprepitant. 34. A pharmaceutical composition comprising: a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a second agent selected from the group consisting of anti-emetics, prokinetics, and histamine H1 antagonists.

Details for Patent 8,003,792

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2024-09-13
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2024-09-13
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2024-09-13